New insights on the consequences of biotransformation processes on the distribution and pharmacodynamic profiles of some neuropsychotropic drugs

European Neuropsychopharmacology

Volumn 22, Issue 5, 2012, Pages 319-329

  Voicu, Victor A ^a   de Leon, Jose ^b   Medvedovici, Andrei Valentin ^c   Rǎdulescu, Flavian Ştefan ^a   Miron, Dalia Simona ^a  

^a CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b Eastern State Hospital   (United States)

^c UNIVERSITY OF BUCHAREST   (Romania)

Author keywords

Clozapine; Clozapine N desmethyl; Clozapine N oxide; Paliperidone; Risperidone; Tramadol; Tramadol O desmethyl

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; OLANZAPINE; RISPERIDONE; TRAMADOL;

BIOTRANSFORMATION; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DISTRIBUTION; FATIGUE; FEMALE; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; MALE; NAUSEA; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; VERTIGO;

ANIMALS; BIOTRANSFORMATION; BLOOD-BRAIN BARRIER; HUMANS; PERMEABILITY; PSYCHOTROPIC DRUGS; TISSUE DISTRIBUTION;

EID: 84859214561     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2011.08.004     Document Type: Review

References (62)

1. Arakawa R., Ito H., Takano A., Takahashi H., Morimoto T., Sassa T., Ohta K., Kato M., Okubo Y., Suhara T. Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. Psychopharmacology 2008, 197:229-235.
2. Aravagiri M., Yuwiler A., Marder S.R. Distribution after repeated oral administration of different dose levels of risperidone and 9-hydroxy-risperidone in the brain and other tissues of rat. Psychopharmacology 1998, 139:356-363.
3. Baumann P., Hiemke C., Ulrich S., Eckermann G., Gaertner I., Gerlach M., Kuss H.J., Laux G., Muller-Oerlinghausen B., Rao M.L., Riederer P., Zernig G. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 2004, 37:243-265.
4. Bergstrom C.A. In silico predictions of drug solubility and permeability: two rate-limiting barriers to oral drug absorption. Basic Clin. Pharmacol. Toxicol. 2005, 96:156-161.
5. Bodor N., Tóth-Sarudy E., Holm T., Pallagi I., Vass E., Buchwald P., Langel U. Novel, cell-penetrating molecular transporters with flexible backbones and permanently charged side-chains. J. Pharm. Pharmacol. 2007, 59:1065-1076.
6. Boulton D.W., DeVane C.L., Liston H.L., Markowitz J.S. In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci. 2002, 71:163-169.
7. Brodie B.B., Gillette J.R. Concepts in Biochemical Pharmacology 1971, Springer-Verlag, Berlin.
8. Burstein E.S., Ma J., Wong S., Gao Y., Pham E., Knapp A.E., Nash N.R., Olsson R., Davis R.E., Hacksell U., Weiner D.M., Brann M.R. Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist. J. Pharmacol. Exp. Ther. 2005, 315:1278-1287.
9. Carrupt P.A., Testa B., Bechalany A., el Tayar N., Descas P., Perrissoud D. Morphine 6-glucuronide and morphine 3-glucuronide as molecular chameleons with unexpected lipophilicity. J. Med. Chem. 1991, 34:1272-1275.
10. Chinta S.J., Pai H.V., Upadhya S.C., Boyd M.R., Ravindranath V. Constitutive expression and localization of the major drug metabolizing enzyme, cytochrome P4502D in human brain. Brain Res. Mol. Brain Res. 2002, 103:49-61.
11. Davidson M., Kahn R.S., Stern R.G., Hirschowitz J., Apter S., Knott P., Davis K.L. Treatment with clozapine and its effect on plasma homovanillic acid and norepinephrine concentrations in schizophrenia. Psychiatry Res. 1993, 46:151-163.
12. Davidson M., Emsley R., Kramer M., Ford L., Pan G., Lim P., Eerdekens M. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr. Res. 2007, 93:117-130.
13. de Leon J., Nikoloff M. Paradoxical excitation on diphenhydramine may be associated with being a CYP2D6 ultrarapid metabolizer: three case reports. CNS Spectr. 2008, 13:133-135.
14. de Leon J., Susce M.T., Pan R.M., Fairchild M., Koch W.H., Wedlund P.J. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J. Clin. Psychiatry 2005, 66:15-27.
15. de Leon J., Wynn G., Sandson N.B. The pharmacokinetics of paliperidone versus risperidone. Psychosomatics 2010, 51:80-88.
16. Didziapetris R., Japertas P., Avdeef A., Petrauskas A. Classification analysis of P-glycoprotein substrate specificity. J. Drug Target. 2003, 11:391-406.
17. Estabrook R.W. A passion for P450s (rememberances of the early history of research on cytochrome P450). Drug Metab. Dispos. 2003, 31:1461-1473.
18. Feng B., Mills J.B., Davidson R.E., Mireles R.J., Janiszewski J.S., Troutman M.D., de Morais S.M. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. Drug Metab. Dispos. 2008, 36:268-275.
19. Fischer H., Gottschlich R., Seelig A. Blood-brain barrier permeation: molecular parameters governing passive diffusion. J. Membr. Biol. 1998, 165:201-211.
20. Frances B., Gout R., Monsarrat B., Cros J., Zajac J.M. Further evidence that morphine-6 beta-glucuronide is a more potent opioid agonist than morphine. J. Pharmacol. Exp. Ther. 1992, 262:25-31.
21. Garcia-Quetglas E., Azanza J.R., Sadaba B., Munoz M.J., Gil I., Campanero M.A. Pharmacokinetics of tramadol enantiomers and their respective phase I metabolites in relation to CYP2D6 phenotype. Pharmacol. Res. 2007, 55:122-130.
22. Gillen C., Haurand M., Kobelt D.J., Wnendt S. Affinity, potency and efficacy of tramadol and its metabolites at the cloned human mu-opioid receptor. Naunyn Schmiedebergs Arch. Pharmacol. 2000, 362:116-121.
23. Goodwin J.T., Conradi R.A., Ho N.F., Burton P.S. Physicochemical determinants of passive membrane permeability: role of solute hydrogen-bonding potential and volume. J. Med. Chem. 2001, 44:3721-3729.
24. Gorg P., Verma J., Roy N. In silico modeling for blood-brain barrier permeability protection. Drug Absorption Studies 2008, 510-556. Springer, New York. C. Ehrhardt, K.J. Kim (Eds.).
25. Hammarlund-Udenaes M., Friden M., Syvanen S., Gupta A. On the rate and extent of drug delivery to the brain. Pharm. Res. 2008, 25:1737-1750.
26. Hendset M., Haslemo T., Rudberg I., Refsum H., Molden E. The complexity of active metabolites in therapeutic drug monitoring of psychotropic drugs. Pharmacopsychiatry 2006, 39:121-127.
27. Hiemke C. Clinical utility of drug measurement and pharmacokinetics: therapeutic drug monitoring in psychiatry. Eur. J. Clin. Pharmacol. 2008, 64:159-166.
28. Kapur S., Langlois X., Vinken P., Megens A.A., De Coster R., Andrews J.S. The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. J. Pharmacol. Exp. Ther. 2002, 302:1129-1134.
29. Kelder J., Grootenhuis P.D., Bayada D.M., Delbressine L.P., Ploemen J.P. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharm. Res. 1999, 16:1514-1519.
30. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 2001, 46:3-26.
31. Liska D., Lyon M., Jones D.S. Detoxification and biotransformational imbalances. Explore (NY) 2006, 2:122-140.
32. Migliardi G., Spina E., D'Arrigo C., Gagliano A., Germano E., Siracusano R., Diaz F.J., de Leon J. Short- and long-term effects on prolactin of risperidone and olanzapine treatments in children and adolescents. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33:1496-1501.
33. Miksys S., Tyndale R.F. The unique regulation of brain cytochrome P450 2 (CYP2) family enzymes by drugs and genetics. Drug Metab. Rev. 2004, 36:313-333.
34. Murphy P.J. The development of drug metabolism research as expressed in the publications of ASPET: Part 1, 1909-1958. Drug Metab. Dispos. 2008, 36:1-5.
35. Murphy P.J. The development of drug metabolism research as expressed in the publications of ASPET: part 2, 1959-1983. Drug Metab. Dispos. 2008, 36:981-985.
36. Murphy P.J. The development of drug metabolism research as expressed in the publications of ASPET: part 3, 1984-2008. Drug Metab. Dispos. 2008, 36:1977-1982.
37. Olsen C.K., Brennum L.T., Kreilgaard M. Using pharmacokinetic-pharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics. Eur. J. Pharmacol. 2008, 584:318-327.
38. Pajouhesh H., Lenz G.R. Medicinal chemical properties of successful central nervous system drugs. NeuroRx 2005, 2:541-553.
39. Pardridge W.M. Brain drug development and brain drug targeting. Pharm. Res. 2007, 24:1729-1732.
40. Paul D., Standifer K.M., Inturrisi C.E., Pasternak G.W. Pharmacological characterization of morphine-6 beta-glucuronide, a very potent morphine metabolite. J. Pharmacol. Exp. Ther. 1989, 251:477-483.
41. Ravindranath V., Anandatheerthavarada H.K., Shankar S.K. Xenobiotic metabolism in human brain-presence of cytochrome P-450 and associated mono-oxygenases. Brain Res. 1989, 496:331-335.
42. Schaber G., Stevens I., Gaertner H.J., Dietz K., Breyer-Pfaff U. Pharmacokinetics of clozapine and its metabolites in psychiatric patients: plasma protein binding and renal clearance. Br. J. Clin. Pharmacol. 1998, 46:453-459.
43. Schotte A., Janssen P.F., Gommeren W., Luyten W.H., Van Gompel P., Lesage A.S., De Loore K., Leysen J.E. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 1996, 124:57-73.
44. Seeman P. An update of fast-off dopamine D2 atypical antipsychotics. Am J Psychiatry 2005, 162:1984-1985.
45. Stain-Texier F., Sandouk P., Scherrmann J.M. Intestinal absorption and stability of morphine 6-glucuronide in different physiological compartments of the rat. Drug Metab. Dispos. 1998, 26:383-387.
46. Timbrell J. Principles of Biochemical Toxicology 2000, Taylor and Francis Ltd, London. third ed.
47. van De Waterbeemd H. Which in vitro screens guide the prediction of oral absorption and volume of distribution? Basic Clin. Pharmacol. Toxicol. 2005, 96:162-166.
48. van De Waterbeemd H., Smith D.A. Relations of molecular properties with drug disposition: the case of gastrointestinal absorption and brain penetration. Pharmacokinetic Optimization in Drug Research 2001, 51-64. Verlag Helvetica Chemica Acta, Zurich. B. Testa, H. van De Waterbeemd, G. Folkers, R. Guy (Eds.).
49. van De Waterbeemd H., Camenisch G., Folkers G., Chretien J.R., Raevsky O.A. Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. J. Drug Target. 1998, 6:151-165.
50. van De Waterbeemd H., Smith D.A., Beaumont K., Walker D.K. Property-based design: optimization of drug absorption and pharmacokinetics. J. Med. Chem. 2001, 44:1313-1333.
51. van De Waterbeemd H., Smith D.A., Jones B.C. Lipophilicity in PK design: methyl, ethyl, futile. J. Comput. Aided Mol. Des. 2001, 15:273-286.
52. Varma M.V., Feng B., Obach R.S., Troutman M.D., Chupka J., Miller H.R., El-Kattan A. Physicochemical determinants of human renal clearance. J. Med. Chem. 2009, 52:4844-4852.
53. Voicu V.A., Radulescu F.S., Miron D.S., Mircioiu C. CYP 2D6 polymorphism and interindividual variability of drug response. a risperidone study case. Rev. Med. Farm. Targu-Mures 2007, 53:265-270.
54. Voicu V.A., Medvedovici A.V., Miron D.S., Radulescu F.S. A novel approach on pharmacokinetic/pharmacodynamic correlations of risperidone: understanding its safety and efficacy profiles. Acta Endocrinol. (Buc) 2010, 6:265-285.
55. Voicu V.A., Thiermann H., Radulescu F.S., Mircioiu C., Miron D.S. The toxicokinetics and toxicodynamics of organophosphonates versus the pharmacokinetics and pharmacodynamics of oxime antidotes: biological consequences. Basic Clin. Pharmacol. Toxicol. 2010, 106:73-85.
56. Wang J.S., Ruan Y., Taylor R.M., Donovan J.L., Markowitz J.S., DeVane C.L. The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein. Int. J. Neuropsychopharmacol. 2004, 7:415-419.
57. Weigmann H., Hartter S., Fischer V., Dahmen N., Hiemke C. Distribution of clozapine and desmethylclozapine between blood and brain in rats. Eur. Neuropsychopharmacol. 1999, 9:253-256.
58. Weiner D.M., Meltzer H.Y., Veinbergs I., Donohue E.M., Spalding T.A., Smith T.T., Mohell N., Harvey S.C., Lameh J., Nash N., Vanover K.E., Olsson R., Jayathilake K., Lee M., Levey A.I., Hacksell U., Burstein E.S., Davis R.E., Brann M.R. The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacology 2004, 177:207-216.
59. Williams R.T. Detoxication Mechanisms 1947, John Wiley and Sons, New York.
60. Wu D., Kang Y.S., Bickel U., Pardridge W.M. Blood-brain barrier permeability to morphine-6-glucuronide is markedly reduced compared with morphine. Drug Metab. Dispos. 1997, 25:768-771.
61. Yasui-Furukori N., Hidestrand M., Spina E., Facciola G., Scordo M.G., Tybring G. Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab. Dispos. 2001, 29:1263-1268.
62. Zhang L., Zhu H., Oprea T.I., Golbraikh A., Tropsha A. QSAR modeling of the blood-brain barrier permeability for diverse organic compounds. Pharm. Res. 2008, 25:1902-1914.